ecteinascidin 743 has been researched along with Connective and Soft Tissue Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baruchel, S; Fox, E; Gonzalez, M; Hillewaert, V; Ouellet, D; Perez-Ruixo, JJ; Poggesi, I; Valenzuela, B | 1 |
| Araki, N; Hiraga, H; Hiruma, T; Horiuchi, K; Kawai, A; Kikuta, K; Kunisada, T; Matsumine, A; Morioka, H; Nakayama, R; Nishimoto, K; Sugiura, H; Susa, M; Takahashi, M; Takahashi, S; Ueda, T; Yonemoto, T | 1 |
1 trial(s) available for ecteinascidin 743 and Connective and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Chondrosarcoma; Chondrosarcoma, Mesenchymal; Dioxoles; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasms, Connective and Soft Tissue; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2016 |
1 other study(ies) available for ecteinascidin 743 and Connective and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Population pharmacokinetics of trabectedin in adolescent patients with cancer.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Agents, Alkylating; Body Surface Area; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; Male; Medication Therapy Management; Neoplasms, Connective and Soft Tissue; Neuroectodermal Tumors, Primitive; Pediatrics; Trabectedin | 2019 |